HK Stock MarketDetailed Quotes

01873 VIVA BIOTECH

Watchlist

0.900
-0.030-3.23%

Market Closed Dec 13 16:08 CST

1.92BMarket Cap-15.25P/E (TTM)

VIVA BIOTECH Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

-14.04%981.82M

-9.42%2.16B

3.02%1.14B

13.10%2.38B

8.02%1.11B

201.90%2.1B

419.57%1.03B

115.74%696.96M

38.79%197.56M

53.81%323.06M

Operating income

-14.04%981.82M

-9.42%2.16B

3.02%1.14B

13.10%2.38B

8.02%1.11B

201.90%2.1B

419.57%1.03B

115.74%696.96M

38.79%197.56M

53.81%323.06M

Cost of sales

12.71%-642.68M

9.39%-1.42B

3.61%-736.22M

-7.63%-1.56B

-7.55%-763.78M

-270.60%-1.45B

-628.84%-710.18M

-134.53%-392.09M

-38.31%-97.44M

-59.87%-167.18M

Operating expenses

12.71%-642.68M

9.39%-1.42B

3.61%-736.22M

-7.63%-1.56B

-7.55%-763.78M

-270.60%-1.45B

-628.84%-710.18M

-134.53%-392.09M

-38.31%-97.44M

-59.87%-167.18M

Gross profit

-16.46%339.15M

-9.47%738.43M

17.68%405.97M

25.30%815.68M

9.07%344.97M

113.53%650.98M

215.90%316.28M

95.59%304.87M

39.26%100.12M

47.81%155.87M

Selling expenses

20.54%-57.56M

-1.33%-132.55M

-29.57%-72.44M

-39.19%-130.8M

-61.04%-55.91M

-617.63%-93.97M

-1,679.40%-34.72M

-266.70%-13.1M

-6.21%-1.95M

9.02%-3.57M

Administrative expenses

10.80%-117.21M

-1.26%-277.11M

7.79%-131.4M

-20.92%-273.65M

-41.94%-142.5M

-105.43%-226.31M

-170.98%-100.39M

-115.10%-110.16M

-65.70%-37.05M

-100.25%-51.22M

Research and development expenses

44.16%-42.83M

5.79%-127.97M

-87.45%-76.7M

-47.04%-135.84M

-9.18%-40.92M

-39.89%-92.38M

-67.87%-37.48M

-46.91%-66.04M

-42.96%-22.32M

-78.03%-44.95M

Revaluation surplus

353.17%64.43M

145.93%162.64M

238.90%14.22M

-293.35%-354.13M

-117.28%-10.24M

71.26%183.15M

-11.11%59.25M

-50.86%106.94M

38.39%66.66M

218.70%217.63M

-Changes in the fair value of financial assets

353.17%64.43M

96.79%-11.68M

238.90%14.22M

-897.31%-364.18M

-117.28%-10.24M

-57.29%45.68M

-11.11%59.25M

-50.86%106.94M

38.39%66.66M

218.70%217.63M

-Changes in the fair value of other assets

----

1,634.56%174.32M

----

-92.69%10.05M

----

--137.48M

----

Impairment and provision

-743.71%-4.69M

13.65%-8.13M

88.57%-556K

-566.03%-9.41M

-4,482.88%-4.87M

53.35%-1.41M

125.58%111K

-67.16%-3.03M

67.22%-434K

-1,503.54%-1.81M

-Other impairment is provision

-743.71%-4.69M

13.65%-8.13M

88.57%-556K

-566.03%-9.41M

-4,482.88%-4.87M

53.35%-1.41M

125.58%111K

-67.16%-3.03M

67.22%-434K

-1,503.54%-1.81M

Operating interest expense

----

7.28%-89.1M

----

---96.1M

-2,648.08%-62.13M

----

-305.92%-2.26M

Special items of operating profit

347.77%35.58M

-25.95%-234.7M

80.85%-14.36M

-268.24%-186.34M

-363.39%-74.97M

225.95%110.76M

5.31%28.47M

-25.27%33.98M

76.17%27.03M

454.68%45.47M

Operating profit

73.86%216.87M

143.95%120.63M

269.65%124.74M

-151.71%-274.49M

-154.29%-73.52M

177.44%530.81M

2.55%135.42M

-39.29%191.33M

41.39%132.05M

149.10%315.16M

Financing cost

64.37%-31.35M

4.38%-176.58M

---87.98M

-0.86%-184.67M

----

---183.11M

----

---38.59M

----

Share of profit from joint venture company

----

---487K

---321K

----

Special items of earning before tax

----

175.19%10.05M

----

97.83%-13.37M

-1,497.78%-547.05M

-1,697.79%-615.53M

-65.74%-34.24M

Earning before tax

404.78%185.52M

87.81%-55.95M

157.90%36.75M

-232.06%-459.17M

-152.00%-63.47M

197.61%347.7M

123.36%122.05M

-226.80%-356.21M

-983.08%-522.39M

165.37%280.93M

Tax

-78.75%-41.28M

2.70%-43.84M

-6.19%-23.09M

4.43%-45.06M

17.16%-21.75M

-108.04%-47.14M

-233.19%-26.25M

-50.53%-22.66M

37.76%-7.88M

1.69%-15.05M

After-tax profit from continuing operations

955.99%144.24M

80.21%-99.79M

116.03%13.66M

-267.76%-504.22M

-188.95%-85.22M

179.33%300.56M

118.07%95.8M

-242.50%-378.87M

-1,240.47%-530.27M

193.62%265.87M

Earning after tax

955.99%144.24M

80.21%-99.79M

116.03%13.66M

-267.76%-504.22M

-188.95%-85.22M

179.33%300.56M

118.07%95.8M

-242.50%-378.87M

-1,240.47%-530.27M

193.62%265.87M

Minority profit

116.90%27.43M

-32.70%16.32M

111.44%12.65M

86.38%24.26M

-44.53%5.98M

62.47%13.01M

--10.78M

--8.01M

----

Profit attributable to shareholders

11,430.90%116.81M

78.03%-116.11M

101.11%1.01M

-283.79%-528.48M

-207.27%-91.2M

174.32%287.55M

116.03%85.02M

-245.51%-386.88M

-1,240.47%-530.27M

193.62%265.87M

Basic earnings per share

4,900.00%0.05

78.57%-0.06

102.00%0.001

-286.67%-0.28

-225.00%-0.05

160.00%0.15

110.53%0.04

-231.58%-0.25

-1,050.00%-0.38

137.50%0.19

Diluted earnings per share

4,900.00%0.05

50.00%-0.14

102.00%0.001

-450.00%-0.28

-225.00%-0.05

132.00%0.08

110.53%0.04

-238.89%-0.25

-1,366.67%-0.38

125.00%0.18

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

Deloitte Guan Huang Chen Fang Certified Public Accountants

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	-14.04%981.82M	-9.42%2.16B	3.02%1.14B	13.10%2.38B	8.02%1.11B	201.90%2.1B	419.57%1.03B	115.74%696.96M	38.79%197.56M	53.81%323.06M
Operating income	-14.04%981.82M	-9.42%2.16B	3.02%1.14B	13.10%2.38B	8.02%1.11B	201.90%2.1B	419.57%1.03B	115.74%696.96M	38.79%197.56M	53.81%323.06M
Cost of sales	12.71%-642.68M	9.39%-1.42B	3.61%-736.22M	-7.63%-1.56B	-7.55%-763.78M	-270.60%-1.45B	-628.84%-710.18M	-134.53%-392.09M	-38.31%-97.44M	-59.87%-167.18M
Operating expenses	12.71%-642.68M	9.39%-1.42B	3.61%-736.22M	-7.63%-1.56B	-7.55%-763.78M	-270.60%-1.45B	-628.84%-710.18M	-134.53%-392.09M	-38.31%-97.44M	-59.87%-167.18M
Gross profit	-16.46%339.15M	-9.47%738.43M	17.68%405.97M	25.30%815.68M	9.07%344.97M	113.53%650.98M	215.90%316.28M	95.59%304.87M	39.26%100.12M	47.81%155.87M
Selling expenses	20.54%-57.56M	-1.33%-132.55M	-29.57%-72.44M	-39.19%-130.8M	-61.04%-55.91M	-617.63%-93.97M	-1,679.40%-34.72M	-266.70%-13.1M	-6.21%-1.95M	9.02%-3.57M
Administrative expenses	10.80%-117.21M	-1.26%-277.11M	7.79%-131.4M	-20.92%-273.65M	-41.94%-142.5M	-105.43%-226.31M	-170.98%-100.39M	-115.10%-110.16M	-65.70%-37.05M	-100.25%-51.22M
Research and development expenses	44.16%-42.83M	5.79%-127.97M	-87.45%-76.7M	-47.04%-135.84M	-9.18%-40.92M	-39.89%-92.38M	-67.87%-37.48M	-46.91%-66.04M	-42.96%-22.32M	-78.03%-44.95M
Revaluation surplus	353.17%64.43M	145.93%162.64M	238.90%14.22M	-293.35%-354.13M	-117.28%-10.24M	71.26%183.15M	-11.11%59.25M	-50.86%106.94M	38.39%66.66M	218.70%217.63M
-Changes in the fair value of financial assets	353.17%64.43M	96.79%-11.68M	238.90%14.22M	-897.31%-364.18M	-117.28%-10.24M	-57.29%45.68M	-11.11%59.25M	-50.86%106.94M	38.39%66.66M	218.70%217.63M
-Changes in the fair value of other assets	----	1,634.56%174.32M	----	-92.69%10.05M	----	--137.48M	----	----	----	----
Impairment and provision	-743.71%-4.69M	13.65%-8.13M	88.57%-556K	-566.03%-9.41M	-4,482.88%-4.87M	53.35%-1.41M	125.58%111K	-67.16%-3.03M	67.22%-434K	-1,503.54%-1.81M
-Other impairment is provision	-743.71%-4.69M	13.65%-8.13M	88.57%-556K	-566.03%-9.41M	-4,482.88%-4.87M	53.35%-1.41M	125.58%111K	-67.16%-3.03M	67.22%-434K	-1,503.54%-1.81M
Operating interest expense	----	----	----	----	7.28%-89.1M	----	---96.1M	-2,648.08%-62.13M	----	-305.92%-2.26M
Special items of operating profit	347.77%35.58M	-25.95%-234.7M	80.85%-14.36M	-268.24%-186.34M	-363.39%-74.97M	225.95%110.76M	5.31%28.47M	-25.27%33.98M	76.17%27.03M	454.68%45.47M
Operating profit	73.86%216.87M	143.95%120.63M	269.65%124.74M	-151.71%-274.49M	-154.29%-73.52M	177.44%530.81M	2.55%135.42M	-39.29%191.33M	41.39%132.05M	149.10%315.16M
Financing cost	64.37%-31.35M	4.38%-176.58M	---87.98M	-0.86%-184.67M	----	---183.11M	----	----	---38.59M	----
Share of profit from joint venture company	----	----	----	----	----	----	----	---487K	---321K	----
Special items of earning before tax	----	----	----	----	175.19%10.05M	----	97.83%-13.37M	-1,497.78%-547.05M	-1,697.79%-615.53M	-65.74%-34.24M
Earning before tax	404.78%185.52M	87.81%-55.95M	157.90%36.75M	-232.06%-459.17M	-152.00%-63.47M	197.61%347.7M	123.36%122.05M	-226.80%-356.21M	-983.08%-522.39M	165.37%280.93M
Tax	-78.75%-41.28M	2.70%-43.84M	-6.19%-23.09M	4.43%-45.06M	17.16%-21.75M	-108.04%-47.14M	-233.19%-26.25M	-50.53%-22.66M	37.76%-7.88M	1.69%-15.05M
After-tax profit from continuing operations	955.99%144.24M	80.21%-99.79M	116.03%13.66M	-267.76%-504.22M	-188.95%-85.22M	179.33%300.56M	118.07%95.8M	-242.50%-378.87M	-1,240.47%-530.27M	193.62%265.87M
Earning after tax	955.99%144.24M	80.21%-99.79M	116.03%13.66M	-267.76%-504.22M	-188.95%-85.22M	179.33%300.56M	118.07%95.8M	-242.50%-378.87M	-1,240.47%-530.27M	193.62%265.87M
Minority profit	116.90%27.43M	-32.70%16.32M	111.44%12.65M	86.38%24.26M	-44.53%5.98M	62.47%13.01M	--10.78M	--8.01M	----	----
Profit attributable to shareholders	11,430.90%116.81M	78.03%-116.11M	101.11%1.01M	-283.79%-528.48M	-207.27%-91.2M	174.32%287.55M	116.03%85.02M	-245.51%-386.88M	-1,240.47%-530.27M	193.62%265.87M
Basic earnings per share	4,900.00%0.05	78.57%-0.06	102.00%0.001	-286.67%-0.28	-225.00%-0.05	160.00%0.15	110.53%0.04	-231.58%-0.25	-1,050.00%-0.38	137.50%0.19
Diluted earnings per share	4,900.00%0.05	50.00%-0.14	102.00%0.001	-450.00%-0.28	-225.00%-0.05	132.00%0.08	110.53%0.04	-238.89%-0.25	-1,366.67%-0.38	125.00%0.18
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	--	Unqualified Opinion	--	--	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion
Auditor	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Deloitte Guan Huang Chen Fang Certified Public Accountants

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

CRO

Intraday-2.25%

01873 VIVA BIOTECH

VIVA BIOTECH Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow